A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises

Trial Profile

A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Crizanlizumab (Primary)
  • Indications Sickle cell anaemia
  • Focus Therapeutic Use
  • Acronyms SUSTAIN
  • Sponsors Reprixys Pharmaceuticals Corporation; Selexys Pharmaceuticals
  • Most Recent Events

    • 25 Jun 2017 Results of post hoc analysis evaluating patients who did not experience Sickle cell-related pain crises, presented at the 22nd Congress of the European Haematology Association.
    • 18 May 2017 According to a Novartis media release, data from this study will be presented at 22nd Annual Congress of the European Hematology Association (EHA).
    • 28 Feb 2017 Results assessing safety and efficacy, published in the JAMA: the Journal of the American Medical Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top